表紙
市場調査レポート

乾癬性関節炎の世界市場 (2015〜2019年)

Global Psoriatic Arthritis Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 347468
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
乾癬性関節炎の世界市場 (2015〜2019年) Global Psoriatic Arthritis Market 2015-2019
出版日: 2015年12月16日 ページ情報: 英文 101 Pages
概要

乾癬性関節炎とは、人体の遠位関節や骨盤の背面・仙腸関節に生じる慢性の炎症性疾患です。世界の乾癬性関節炎の患者数は緩やかな増加傾向にあり、それに合わせて治療薬の市場規模も今後安定的に伸びていくと思われます。また、様々な新製品も開発・上市されており、それが市場成長を後押ししています。地域別にみると、南北アメリカが世界全体の40%以上を占めています。

当レポートでは、世界の乾癬性関節炎の市場について分析し、疾患の概要や市場構造、主なパイプライン製品とその特長、市場規模の動向 (今後5年間の予測値)、薬剤の種類別 (剤型・投与経路・作用機序など) および地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブ・サマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要
  • 大手ベンダーの主要製品

第3章 製品のプロファイル

第4章 市場分析の手法

  • 分析手法
  • 経済指標

第5章 イントロダクション

  • 市場動向の概略

第5章 市場環境

  • 市場構造
  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第6章 疾患の概要

  • 疾患の基礎知識
  • 乾癬性関節炎の種類
  • 症状
  • リスク要因
  • 診断
  • 疾患管理
  • QoL (生活の質)
  • 疫学

第7章 パイプライン製品のプロファイル

第8章 パイプライン候補薬の新たな標的・作用機序

  • 小分子
  • 生物製剤

第9章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第10章 作用機序 (MoA) による市場区分

  • 腫瘍壊死因子 (TNF) -α阻害剤
  • ホスホジエステラーゼ4 (PDE4) 阻害剤
  • インターロイキン (IL) 遮断薬
  • その他

第11章 分子の種類別の市場区分

  • 生物製剤
  • 小分子

第12章 疾患の重症度別の市場区分

第13章 投薬経路別の市場区分

  • 経口薬
  • 非経口薬
  • 局所投与

第14章 剤型別の市場区分

  • 固体
  • 液体
  • 半固体

第15章 地域区分

  • 南北アメリカ市場
  • 欧州・中東・アフリカ諸国 (EMEA) 市場
  • アジア太平洋地域市場

第16章 市場促進要因

  • 一般的な認知度の上昇
  • 医療上のアンメットニーズ
  • 患者人口の増加
  • 生活パターンの変化

第17章 促進要因の影響力

第18章 市場の課題

  • 生物製剤のコスト上昇
  • ブランド薬の特許満了
  • 患者による補完/代替療法 (CAM) の利用
  • 薬剤の副作用

第19章 促進要因・課題の影響力

第20章 市場の動向

  • バイオシミラーの登場
  • 適応外/従来型オプションの人気の高さ
  • 米国における患者支援計画
  • 生物製剤が市場を独占

第21章 ベンダー環境

  • 競争シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第22章 主要ベンダーの分析

  • AbbVie
  • Amgen
  • Celgene
  • Janssen Pharmaceuticals
  • UCB

第23章 付録

  • 略語集

第24章 Technavioについて

図表一覧

目次
Product Code: IRTNTR7499

Market outlook of the psoriatic arthritis market

Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.

In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.

Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers

The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • TNF inhibitors
  • PDE4 inhibitors
  • Interleukin blockers
  • Others

Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis

The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • Mild psoriatic arthritis
  • Moderate psoriatic arthritis
  • Severe psoriatic arthritis

Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals

This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.

Leading vendors in this market are -

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Celgene
  • UCB

Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the psoriatic arthritis market?
  • What are the key market trends impacting the growth of the psoriatic arthritis market?
  • What are the challenges to market growth?
  • Who are the key vendors in the psoriatic arthritis market?
  • What are the market opportunities and threats faced by the vendors in the psoriatic arthritis market?
  • Trending factors influencing the market shares of APAC, EMEA, and the Americas?
  • What are the key outcomes of the five forces analysis of the psoriatic arthritis market?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Disease overview

  • Understanding the disease
  • Types of psoriatic arthritis
  • Symptoms
  • Risk factors
  • Diagnosis
  • Disease management
  • Quality of life
  • Epidemiology

PART 07: Pipeline portfolio

PART 08: Novel mechanisms targeted by pipeline candidates

  • Small molecules
  • Biologics

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by MoA

  • TNF-alpha inhibitors
  • PDE4 inhibitors
  • IL blockers
  • Others

PART 11: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 12: Market segmentation by severity of disease

PART 13: Market segmentation by route of administration

  • Oral
  • Parenteral
  • Topical

PART 14: Market segmentation by dosage form

  • Solid
  • Liquid
  • Semi-solid

PART 15: Geographical segmentation

  • Psoriatic arthritis market in Americas
  • Psoriatic arthritis market in EMEA
  • Psoriatic arthritis market in APAC

PART 16: Market drivers

  • Increase in public awareness
  • Unmet medical needs
  • Growing patient population
  • Change in lifestyle patterns

PART 17: Impact of drivers

PART 18: Market challenges

  • Increasing costs of biologics
  • Loss of patent exclusivity of branded therapies
  • Use of CAM by patients
  • Adverse effects of drugs

PART 19: Impact of drivers and challenges

PART 20: Market trends

  • Emergence of biosimilars
  • Popularity of off-label and traditional treatment options
  • Patient assistance programs in the US
  • Dominance of market by biologics

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 22: Key vendor analysis

  • AbbVie
  • Amgen
  • Celgene
  • Janssen Pharmaceuticals
  • UCB

PART 23: Appendix

  • List of abbreviations

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings 7
  • Exhibit 02: Types of psoriatic arthritis
  • Exhibit 03: Signs and symptoms of psoriatic arthritis
  • Exhibit 04: Risk factors for psoriatic arthritis
  • Exhibit 05: Diagnostic test for psoriatic arthritis
  • Exhibit 06: Treatment options for psoriatic arthritis
  • Exhibit 07: Management of psoriatic arthritis
  • Exhibit 08: Pipeline molecules for psoriatic arthritis
  • Exhibit 09: Psoriatic arthritis clinical trial by phase
  • Exhibit 10: Psoriatic arthritis clinical trial by status
  • Exhibit 11: Novel targets of the pipeline candidates
  • Exhibit 12: Tofacitinib
  • Exhibit 13: Ixekizumab
  • Exhibit 14: Sekukinumab
  • Exhibit 15: Bimekizumab
  • Exhibit 16: Global psoriatic arthritis market 2014-2019 ($ millions)
  • Exhibit 17: Five forces analysis
  • Exhibit 18: Segmentation of global psoriatic arthritis market by MoA
  • Exhibit 19: Segmentation of global psoriatic arthritis market by MoA 2014
  • Exhibit 20: Segmentation of global psoriatic arthritis market by type of molecule
  • Exhibit 21: Segmentation of global psoriatic arthritis market by severity of disease
  • Exhibit 22: Segmentation of global psoriatic arthritis market by route of administration
  • Exhibit 23: Segmentation of global psoriatic arthritis market by dosage form
  • Exhibit 24: Global psoriatic arthritis market by geography 2014
  • Exhibit 25: Psoriatic arthritis market in Americas 2014-2019 ($ millions)
  • Exhibit 26: Psoriatic arthritis market in EMEA 2014-2019 ($ millions)
  • Exhibit 27: Psoriatic arthritis market in APAC 2014-2019 ($ millions)
  • Exhibit 28: Global psoriatic arthritis market by geography 2014-2019 ($ millions)
  • Exhibit 29: Drivers in global psoriatic arthritis market
  • Exhibit 30: Impact of drivers
  • Exhibit 31: Challenges in global psoriatic arthritis market
  • Exhibit 32: Average annual cost of HUMIRA, Enbrel, and Remicade 2014 ($)
  • Exhibit 33: Approvals and patent expiries of branded biologics
  • Exhibit 34: Impact of drivers and challenges
  • Exhibit 35: Trends in global psoriatic arthritis market
  • Exhibit 36: YoY sales comparison of top drugs 2010-2014 ($ millions)
  • Exhibit 37: YoY sales comparison of top drugs 2010-2014 (%)
  • Exhibit 38: YoY global sales of HUMIRA 2010-2014 ($ millions)
  • Exhibit 39: AbbVie: Key takeaways
  • Exhibit 40: YoY global sales of Remicade 2010-2014 ($ millions)
  • Exhibit 41: YoY global sales of Simponi 2012-2014 ($ millions)
  • Exhibit 42: Janssen Pharmaceuticals: Key takeaways
  • Exhibit 43: YoY sales of Enbrel in US and Canada 2010-2014 (($ millions)
  • Exhibit 44: YoY sales of Enbrel in US 2010-2014 ($ millions)
  • Exhibit 45: YoY sales of Enbrel in Canada 2010-2014 ($ millions)
  • Exhibit 46: YoY sales of Enbrel in Japan 2010-2014 ($ millions)
  • Exhibit 47: Comparison of YoY sales of Enbrel in US, Japan, and Canada 2010-2014 ($ millions)
  • Exhibit 48: Amgen: Key takeaways
  • Exhibit 49: UCB: Key takeaways
  • Exhibit 50: Celgene: Key takeaways
  • Exhibit 51: AbbVie: Product segmentation by revenue 2014
  • Exhibit 52: AbbVie: Geographical segmentation by revenue 2014
  • Exhibit 53: Amgen: Business segmentation by revenue 2014
  • Exhibit 54: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 55: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 56: Celgene: Product segmentation by revenue 2014
  • Exhibit 57: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 58: Celgene: Geographical segmentation by revenue 2014
  • Exhibit 59: Janssen Pharmaceuticals: Key therapeutic areas
  • Exhibit 60: UCB: Product segmentation by revenue 2014
  • Exhibit 61: UCB: Product segmentation by revenue 2013 and 2014
  • Exhibit 62: UCB: Geographical segmentation by revenue 2014
  • Exhibit 63: Geographical segmentation by revenue 2013 and 2014
Back to Top